Chuankezhi Injection for Asthma: Protocol of a Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Aug 16

PMID 31415356

Citations 2

Authors

Meichen Li

Wenjiang Zheng

Chaoyuan Zhang

Qian Yan

Zijing Peng

Fuqi Xie

Yu Hong

Xiaohong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Asthma is a chronic inflammatory disease characterized by recurrent attacks of breathlessness and wheezing, which often worsen at night or in the early morning and vary from person to person in severity and frequency. Chuankezhi injection (CKZ), as a new Chinese medicine, was recently found to have a good clinical effect on asthma. Whereas neither systematic nor meta-analysis of randomized controlled trials (RCTs) explain the efficacy of CKZ in treating asthma. Therefore, we provide a protocol to evaluate the efficacy and safety of CKZ for asthma.

Methods: From inception until April 2019, a systematic and comprehensive literature search will be conducted in both 4 Chinese databases and 3 English databases. RCTs will be included related to CKZ for asthma. We will assess the quality of the included trials in accordance with the risk of bias tools in Cochrane manual 5.1.0. We will use the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method to assess the certainty of the estimated evidence. Data analysis will be performed using the STATA 15.0.

Results: This systematic review aims to assess the effectiveness and safety of CKZ for the treatment of asthma, in order to provide evidence for the clinical practice of Chinese medicine. This protocol will be conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement. The results of this meta-analysis will be submitted to a peer-reviewed journal once it is completed.

Conclusion: The consequence of this study will furnish proof to evaluate if CKZ is effective in the treatment of asthma.

Prospero Registration Number: ROSPERO CRD42019134458.

Citing Articles

Evidence Construction of Chuankezhi Injection Against Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Pharmacology.

Wei X, Zhong Y, Yi X, Li T, Ling Z, Ming M Int J Chron Obstruct Pulmon Dis. 2024; 19:1177-1196.

PMID: 38826697 PMC: 11141582. DOI: 10.2147/COPD.S442281.

Investigation of the Mechanisms of Chuankezhi Injection in the Treatment of Asthma Based on the Network Pharmacology Approach.

Zhu H, Shi Y, Jiang S, Jiao X, Zhu H, Wang R Evid Based Complement Alternat Med. 2021; 2021:5517041.

PMID: 34221070 PMC: 8213469. DOI: 10.1155/2021/5517041.

References

Sobieraj D, Weeda E, Nguyen E, Coleman C, White C, Lazarus S . Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018; 319(14):1485-1496. PMC: 5876810. DOI: 10.1001/jama.2018.2769. View

Peters M, McGrath K, Hawkins G, Hastie A, Levy B, Israel E . Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016; 4(7):574-584. PMC: 5007068. DOI: 10.1016/S2213-2600(16)30048-0. View

Wechsler M, Kelley J, Boyd I, Dutile S, Marigowda G, Kirsch I . Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011; 365(2):119-26. PMC: 3154208. DOI: 10.1056/NEJMoa1103319. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Wei Y, Liu B, Sun J, Lv Y, Luo Q, Liu F . Regulation of Th17/Treg function contributes to the attenuation of chronic airway inflammation by icariin in ovalbumin-induced murine asthma model. Immunobiology. 2015; 220(6):789-97. DOI: 10.1016/j.imbio.2014.12.015. View

Demenais F, Margaritte-Jeannin P, Barnes K, Cookson W, Altmuller J, Ang W . Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat Genet. 2017; 50(1):42-53. PMC: 5901974. DOI: 10.1038/s41588-017-0014-7. View

Stempel D, Szefler S, Pedersen S, Zeiger R, Yeakey A, Lee L . Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med. 2016; 375(9):840-9. DOI: 10.1056/NEJMoa1606356. View

Puhan M, Schunemann H, Murad M, Li T, Brignardello-Petersen R, Singh J . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014; 349:g5630. DOI: 10.1136/bmj.g5630. View

Feng Q, Yu J, Zhan J, Xu Y, Chow Y, Xu S . [In vivo study of Chuankezhi metabolism in rat]. Yao Xue Xue Bao. 2018; 52(3):449-55. View

10.

Hong M, Song Y, Li X . Effects and mechanisms of actions of Chinese herbal medicines for asthma. Chin J Integr Med. 2011; 17(7):483-91. DOI: 10.1007/s11655-011-0780-5. View

11.

Xu S, Zhu Y, Yu J, Feng Y, Sun S, Xu Y . [Simultaneous determination of 4 prenylflavonoids of Chuankezhi injection in rat plasma by LC-MS/MS]. Yao Xue Xue Bao. 2018; 51(4):637-41. View

12.

Chen S, Yang X, Tang X, Li M, Liu S, Liang J . [Systematic review of Chuankezhi injection for treating acute exacerbation of chronic obstructive pulmonary disease]. Zhongguo Zhong Yao Za Zhi. 2017; 42(14):2789-2795. DOI: 10.19540/j.cnki.cjcmm.20170523.009. View

13.

Zhao J, Pan K, Wang Q, Xu Z, Weng D, Li J . Effect of anti-asthma Chinese medicine Chuankezhi on the anti-tumor activity of cytokine-induced killer cells. Chin J Cancer. 2013; 32(10):553-60. PMC: 3845537. DOI: 10.5732/cjc.012.10249. View

14.

Zhai H, Yu J, Zhang Q, Liu H, Zhang J, Song X . Cytotoxic and antibacterial triterpenoids from the roots of Morinda officinalis var. officinalis. Fitoterapia. 2018; 133:56-61. DOI: 10.1016/j.fitote.2018.12.011. View

15.

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

16.

Corren J, Lemanske R, Hanania N, Korenblat P, Parsey M, Arron J . Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365(12):1088-98. DOI: 10.1056/NEJMoa1106469. View

17.

Pandya D, Puttanna A, Balagopal V . Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2015; 8:59-65. PMC: 4319197. DOI: 10.2174/1874306401408010059. View

18.

Sobieraj D, Baker W, Nguyen E, Weeda E, Coleman C, White C . Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018; 319(14):1473-1484. PMC: 5876909. DOI: 10.1001/jama.2018.2757. View

19.

Tang X, Nian H, Li X, Yang Y, Wang X, Xu L . Effects of the combined extracts of Herba Epimedii and Fructus Ligustrilucidi on airway remodeling in the asthmatic rats with the treatment of budesonide. BMC Complement Altern Med. 2017; 17(1):380. PMC: 5540498. DOI: 10.1186/s12906-017-1891-0. View

20.

Price D, Musgrave S, Shepstone L, Hillyer E, Sims E, Gilbert R . Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364(18):1695-707. DOI: 10.1056/NEJMoa1010846. View